Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin

Healthy Male Volunteers Clinical Trial

Official title:

Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01767610
• Other study ID #: HL-PIF-101
• Status: Completed
• Phase: Phase 1
• Start date: January 2013
• Est. completion date: July 2013

Study information

• Verified date: August 2018
• Source: Hanlim Pharm. Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic characteristics of each arms after repeated administrating Lipilfen cap. 160mg and Livalo tab. 2mg through 3 period by separately or combinedly.

Description:

To develop combination product of micronized fenofibrate plus pitavastatin, we would like to evaluate pharmacokinetic drug interaction by comparing the steady-state pharmacokinetic characteristics of each arms after repeated administrating Lipilfen cap. 160mg(micronized fenofibrate 160mg)by Dae Woong Pharma. and Livaro tab. 2mg (pitavastatin Ca 2mg) by Joong Wae Pharm. through 3 period by separately or combinedly.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: July 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Years 20-55

2. Body weight=50kg and 18=BMI=29kg/m2

3. Volunteer

Exclusion Criteria:

1. Subject with serious active cardiovascular, respiratory, hepatology, renal, hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological disease or history of such disease

2. Subject with symptoms of acute disease within 28days prior to study medication dosing

3. Subject with known for history which affect on the absorption, distribution, metabolism or excretion of drug

4. Subject with clinically significant active chronic disease

5. Subject with any of the following conditions in laboratory test i. AST(aspartate aminotransferase) or ALT(alanine transferase) > upper normal limit × 1.5 ii. Total bilirubin > upper normal limit × 1.5 iii. renal failure with Creatinine clearance < 50mL/min iv. creatine phosphokinase > upper normal limit × 2

6. Positive test results for hepatitis B virus surface antigen, anti-hepatitis C virus antibody, venereal disease research laboratory test

7. Use of any prescription medication within 14 days prior to study medication dosing

8. Use of any medication such as over-the-counter medication including oriental medication within 7 days prior to study medication dosing

9. Subject with clinically significant allergic disease (except for mild allergic rhinitis and mild allergic dermatitis that are not needed to administer drug)

10. Subject with known for hypersensitivity reaction to fenofibrate, fenofibric acid or statin

11. gallbladder disease

12. Subject who experiences photo-allergy or photo-toxicity during administrating fibrates or ketoprofen

13. Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption

14. Subject who is not albe to taking the institutional standard meal

15. Subject with whole blood donation within 60days, component blood donation within 20days

16. Subjects receiving blood transfusion within 30days prior to study medication dosing

17. Participation in any clinical investigation within 60days prior to study medication dosing

18. Continued excessive use of caffeine (caffeine > five cups/day), alcohol(alcohol>30g/day) and severe heavy smoker(cigarette > 10 cigarettes per day)

19. Subjects with decision of nonparticipation through investigator's review due to laboratory test results or other excuse such as non-responding to request or instruction by investigator

Related Conditions & MeSH terms

• Healthy Male Volunteers

Intervention

Drug:
• micronized fenofibrate 160mg

• pitavastatin Ca 2mg

• micronized fenofibrate 160mg plus pitavastatin Ca 2mg

Locations

Country	Name	City	State
Korea, Republic of	Kyungpook National University Hospital	Daegu

Sponsors (1)

Lead Sponsor	Collaborator
Hanlim Pharm. Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Drug-Drug interaction evaluation (Cmax,ss, Cmin,ss, Tmax,ss)		just before dosing on 1st day and 4th day of each period and 0, 0.25, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 48hr on final 5th dosing
Secondary	Number of participants with adverse events		Participants will be followed for the duration of study medication dosing days and hospital stay, and expected average of 3days and follow-up period for maximum 7 days from the discharge